Photo of Stephen E.F. Spurgeon, MD

Stephen E.F. Spurgeon MD

Dr. Spurgeon’s research focuses on translating lab findings into new therapies in chronic lymphocytic leukemia and lymphoma, particularly mantle cell lymphoma.Dr. Spurgeon has a  special interest in: 1) unlocking the importance of cell signaling in lymphoid cancer pathogenesis, 2) identifying new therapeutic targets, 3) developing novel clinical trials, and 4) designing personalized treatment approaches.CLL:  Specifically, he is interested in the role of tyrosine kinases and B cell receptor (BCR) mediated signaling in leukemogenesis in chronic lymphocytic leukemia (CLL). He hopes to develop kinase directed treatment approaches for CLL. He also is interested in determining if in vitro kinase targeted drug screens can help predict in vivo response to anti-leukemic therapy. This includes collaborations with Dr. Marc Loriaux, Dr. Jeffrey Tyner and Dr. Brian Druker in the Center for Cell Signaling.Lymphoma: In collaboration with Dr. Craig Okada at OHSU and Dr. Elliot Epner at Penn State, Dr. Spurgeon is exploring the role of epigenetic therapy in B cell malignancies especially in mantle cell lymphoma. Specifically, he is conducting an early phase clinical trial using cladribine, rituximab and vorniostat in relapsed B cell malignancies and newly diagnosed mantle cell lymphoma and CLL. This study evaluates DNA methylation patterns in patients on therapy and hopes to identify important target genes modified by this combination therapy.


  • M.D., Jefferson Medical College at Thomas Jefferson University, Philadelphia Pennsylvania 2002
  • Residency:

    • 2002-2005, residency: Oregon Health & Science University, Portland, Oregon
  • Fellowship:

    • 2006-2009, fellowship: Oregon Health & Science University, Portland, Oregon
  • Certifications:

    • American Board of Internal Medicine (internal medicine), 2005

Memberships and associations

  • American Society of Oncology


  • "Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma" Oncotarget  2015
  • "A phase 1 study of the PI3Kd inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)" Blood May 29 2014
  • "MYD88 mutation analysis of a rare composite chronic lymphocyte leukemia and lymphoplasmacytic lymphoma by flow cytometry cell sorting" Annals of Hematology November 22 2015
  • "Aberrations of MYC are a common event in B-cell prolymphocytic leukemia" American Journal of Clinical Pathology September 1 2014
  • "Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma" Leukemia and Lymphoma August 2011
  • "Chronic lymphocytic leukemia with a FGFR3 translocation" Cancer genetics July 1 2014
  • "Long-term follow-up of MCL patients treated with single-agent ibrutinib" Blood August 6 2015
  • "Assessment of Prostate-Specific Antigen Doubling Time in Prediction of Prostate Cancer on Needle Biopsy" Urology May 2007
  • "Classification and regression tree analysis for the prediction of aggressive prostate cancer on biopsy" Journal of Urology March 2006
  • "Acute promyelocytic leukemia with JAK2 V617F and severe differentiation syndrome" Leukemia Research Reports January 1 2015
  • "The selective syk inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemias" Journal of Pharmacology and Experimental Therapeutics February 2013
  • "A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia" Blood February 27 2014
  • "Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIRâ„¢ therapeutic protein, for relapsed or refractory NHL patients" British Journal of Haematology January 1 2015
  • "Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia" Blood May 29 2014
  • "Improved survival in hairy cell leukaemia over three decades" British Journal of Haematology November 2013
  • "Cladribine" Current Opinion in Investigational Drugs August 2009
  • "Hematology"  May 2004
  • "Survival trends in mantle cell lymphoma in the United States over 16 years 1992-2007" Leukemia and Lymphoma August 2012
  • "Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma" Blood May 29 2014
  • "Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening" Journal of Cancer Research January 1 2013
  • "A potential therapeutic strategy for chronic lymphocytic leukemia by combining idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor" Oncotarget  2014
  • "CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway" Leukemia October 2013
  • "Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma" New England Journal of Medicine  2013
  • "Reversible pulmonary toxicity due to lenalidomide" Journal of Oncology Pharmacy Practice June 2012
  • "Cyclin-dependent kinase inhibitor P1446A induces apoptosis in a JNK/p38 MAPK-dependent manner in chronic lymphocytic leukemia B-cells" PLoS One November 1 2015
  • "Cardiac non-Hodgkin's lymphoma" European Journal of Haematology  2016
  • "Postibrutinib outcomes in patients with mantle cell lymphoma" Blood March 24 2016
  • "Phase 2 study of idelalisib and entospletinib" Blood May 19 2016
  • "Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia" Science Translational Medicine August 31 2016
  • "Ibrutinib is an effective treatment for B-cell prolymphocytic leukaemia" British Journal of Haematology  2016

Additional information

Edit profile